Menu
LAMPGEN CLINICAL INTELLIGENCE
Oncology
Approval Tracker
U.S. FDA oncology decisions since 2020. See the approved population, trace the evidence, and turn each decision into a sourced LinkedIn article brief.
UNITED STATES · FDA
660
verified approval records
- Solid tumors
- 409
- Blood cancers
- 187
- Cancer supportive care
- 64
Archive from Jan 1, 2020 · Sources reviewed Nov 17, 2026
APPROVAL REGISTER
Browse FDA decisions
660 approvals · Latest first
Breast cancer
Wilserdly + everolimus
giredestrant and everolimus · Genentech
Giredestrant with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, identified by an FDA-authorized test, after recurrence during or after adjuvant endocrine-based therapy or progression on a metastatic endocrine-based regimen.
Bladder cancer
Imfinzi + Padcev
durvalumab and enfortumab vedotin-ejfv · AstraZeneca (Imfinzi)
Neoadjuvant durvalumab with enfortumab vedotin-ejfv, followed after radical cystectomy by adjuvant durvalumab alone, for adults with muscle-invasive bladder cancer who cannot receive or have refused cisplatin-based chemotherapy.
Breast cancer
Pebrilzo
pertuzumab-qcay · Biocon Biologics
A Perjeta biosimilar for specified HER2-positive breast cancer combinations: first-line metastatic use with trastuzumab and docetaxel; neoadjuvant use with trastuzumab and chemotherapy for locally advanced, inflammatory or early disease; and adjuvant use with trastuzumab and chemotherapy for early disease at high recurrence risk. The label sets the detailed eligibility limits.
Tenosynovial giant cell tumor
Pimjetmi
pimicotinib · EMD Serono
Pimicotinib for adults with symptomatic tenosynovial giant cell tumor when resection could worsen functional limitation or cause severe morbidity.
Multiple solid tumors and hematologic malignancies
Oxderys
doxorubicin hydrochloride injection · AVYXA Holdings
Doxorubicin injection for multi-agent adjuvant treatment of node-positive breast cancer after resection, and the leukemias, lymphomas and metastatic solid tumors specified in its FDA labeling. The full label defines each authorized use.
Head and neck cancer
Rybrevant Faspro
amivantamab and hyaluronidase-lpuj · Janssen Biotech
Subcutaneous monotherapy for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) after progression on or following platinum chemotherapy and an anti-PD-(L)1 antibody. The use excludes HPV-associated oropharyngeal squamous cell carcinoma.
Prostate cancer
Talzenna + enzalutamide
talazoparib with enzalutamide · Pfizer
Adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer and homologous recombination repair (HRR) gene mutations identified by an FDA-authorized test.
Colorectal cancer
Jemperli
dostarlimab-gxly · GSK
Adults with stage II or III locally advanced rectal cancer that is MSI-high or mismatch repair deficient (dMMR), confirmed using an FDA-authorized solid-tumor test.
Tumor-agnostic solid tumors
Keytruda / Keytruda Qlex
pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph · Merck
Adults and children with unresectable or metastatic solid tumors with a tumor mutational burden (TMB) of at least 13 mutations per megabase by an FDA-authorized test, after prior treatment and without satisfactory alternatives.
Bladder cancer
Anktiva + BCG
nogapendekin alfa inbakicept-pmln with Bacillus Calmette–Guérin · Altor BioScience / ImmunityBio
Adults with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC). This expansion adds high-grade papillary-only tumors to the prior carcinoma-in-situ population.
Colorectal cancer
Tecentriq / Tecentriq Hybreza
atezolizumab or atezolizumab and hyaluronidase-tqjs · Genentech
Adjuvant use with fluoropyrimidine and oxaliplatin in stage III dMMR colon cancer. IV Tecentriq applies from age 2. Subcutaneous Tecentriq Hybreza applies from age 12 and at least 40 kg.
Breast cancer
Tukysa + trastuzumab + pertuzumab
tucatinib with trastuzumab and pertuzumab · Seagen / Pfizer
Maintenance for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
COVERAGE & SOURCES
How we count approvals
We record U.S. FDA approvals of oncology drugs and biologics, including cell therapies, radiopharmaceuticals, original product approvals for established ingredients, new indications, formulations, dosing regimens, reapprovals, traditional conversions, biosimilars and first generics with oncology labeling. The archive includes FDA-reviewed treatments for nonmalignant tumors and oncology-related transplant supportive care.
Entries use the FDA action date. Distinct approved uses can have separate records on the same date. We group formulations when FDA approves the same use together and note any differences in eligibility. Each record describes the use as issued. Later conversions or withdrawals appear where documented by FDA.
We check FDA notices against archived records, annual efficacy supplement reports, Drugs@FDA, the Purple Book and Project Confirm. FDA notices cover only part of approval activity. The register reflects the actions we could verify in available records. The scope excludes repeat generics, devices, stand-alone diagnostics, safety-only and evidence-only label updates, advisory votes, trial readouts and pending decisions.
The review date records when available sources were checked. Monthly tables can lag individual approval letters; later-published decisions are added after verification.
Planning site coverage, monitoring, or a study handoff? Plan coverage for an oncology study milestone ↗
Selected records include a SIGNAL™ question that translates a development into something a study team can check. See the worked example ↗